Ławicki Sławomir, Czygier Małgorzata, Bedkowska Ewa, Wojtukiewicz Marek, Szmitkowski Maciej
Department of Biochemical Diagnostics, Medical Academy, Białystok, Poland.
Pol Arch Med Wewn. 2008 Sep;118(9):464-9.
Macrophage-colony stimulating factor (M-CSF) is one of the glycoproteins called hematopoetic growth factors. The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated. Moreover, diagnostic values were determined through assessing diagnostic sensitivity and specificity as well as predictive value of positive (PV(+xe)) and negative (PV(-ve)) results. The results obtained were compared to the CA 15-3 and a control group.
The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women. M-CSF was assayed using an ELISA method. CA 15-3 was measured by means of an immunoenzymatic method (MEIA) from ABBOT.
Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups. These levels were also significantly higher in patients with more advanced stages of cancer. A positive correlation between M-CSF and CA 15-3 levels was observed. The diagnostic sensitivity of M-CSF (58%), a specificity (93%), PV(+ve) (94%) and PV(-ve) (43%) were higher or equal to the values obtained for CA 15-3 (49%, 93%, 93% and 40%, respectively). When both parameters studied were determined jointly, sensitivity increased to 72%.
The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
巨噬细胞集落刺激因子（M-CSF）是被称为造血生长因子的糖蛋白之一。体外肿瘤细胞系和体内实体瘤中均有该细胞因子直接产生的报道。
在本研究中，评估了乳腺癌患者和乳腺良性肿瘤患者体内M-CSF的水平。此外，通过评估诊断敏感性、特异性以及阳性（PV(+ve)）和阴性（PV(-ve)）结果的预测价值来确定其诊断价值。将所得结果与CA 15-3及一个对照组进行比较。
研究组由70例乳腺癌患者、20例良性肿瘤患者组成，对照组由30名健康女性组成。采用酶联免疫吸附测定（ELISA）法检测M-CSF。采用雅培公司的免疫酶法（MEIA）测定CA 15-3。
与良性肿瘤组和对照组相比，乳腺癌患者体内M-CSF和CA 15-3水平在统计学上显著更高。癌症分期越晚的患者，这些水平也显著更高。观察到M-CSF与CA 15-水平之间呈正相关。M-CSF的诊断敏感性（58%）、特异性（93%）、PV(+ve)（94%）和PV(-ve)（43%）高于或等于CA 15-3的相应值（分别为49%、93%、93%和40%）。当联合测定两个研究参数时，敏感性提高到72%。
上述数据表明，M-CSF可能对乳腺良性肿瘤和乳腺癌的诊断及鉴别诊断有用（临床进展程度最低者除外）。
